About the Study

Infant Leukemia: A study of revumenib (SNDX-5613) in combination with chemotherapy in infants with relapsed or refractory KMT2A-rearranged infant leukemia

This study is for: • Patients ages 1 month to less than 6 years old • Who have been diagnosed with KMT2A-rearranged infant leukemia that has relapsed (has come back) or is refractory (has not responded to earlier treatment) The medicine, revumenib (SNDX-5613), has been shown to specifically kill these cancer cells with KMT2A rearrangement in laboratory experiments. Early studies with revumenib have been conducted in adults and pediatrics. The goals of this study are to find what effects, good and/or bad, the drug revumenib in combination with chemotherapy has on infants with relapsed or refractory leukemia and to learn more about the pharmacology (for example, the best dose) of the medication.

Interested in learning more?

Full Study Name: AALL2121